FDA approves Alzheimer’s therapy despite mixed evidence
The FDA’s decision to approve the drug, siding with industry and patient advocates, raises new questions about whether it is lowering its burden of proof for drugmakers.
The FDA’s decision to approve the drug, siding with industry and patient advocates, raises new questions about whether it is lowering its burden of proof for drugmakers.
The FDA’s decision to approve the drug, siding with industry and patient advocates, raises new questions about whether it is lowering its burden of proof for drugmakers.
The finding could pave the way for the shot to become the second authorized in the U.S. for use in teens.
The finding could pave the way for the shot to become the second authorized in the U.S. for use in teens.
The finding could pave the way for the shot to become the second authorized in the U.S. for use in teens.
The finding could pave the way for the shot to become the second authorized in the U.S. for use in teens.